Evidence Table E59. Binge eating disorder drug treatment – part 5

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Arnold, 200266 | Binges/wk | Binges/wk:  G1: 6.0 (2.5)  G2: 6.1 (4.8)  (P = NS) | Binges/wk  Endpoint:  G1: 1.8 (2.9)  G2: 2.7 (3.8)  Diff between groups (P = NR)  Diff between groups in change over time (time trend analysis, P = 0.033; endpoint analysis, P = NS)  Response Categories (% decrease in binges/wk from baseline to endpoint)  Intent to treat sample: G1 = 29; G2 = 21  None (<50%): G1: 7 (24); G2: 9 (43)  Moderate (50%-74% decrease): G1: 8 (28); G2: 4 (19)  Marked (75%-99% decrease): G1: 1 (3); G2: 3 (14)  Remission (100%): G1: 13 (45) (P = NR) G2: 5 (24) (P = NR)  Diff between groups (P = NS)  Diff between groups in change over time (P = NR) |
| Brownley, 201367 | Binges per 28 days | Binges per 28 days  baseline  G1: 31.0 (24.8)  G2: 12.8 (3.6)  G3: 16.7 (9.5)  p = 0.39 | Binges per 28 days  Monthly rate of change  G1: -1.65 (0.76)  G2: -0.93 (0.70)  G3: -0.97 (0.78)  p = NS |

Evidence Table E59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Guerdjikova, 200968 | Binges/wk  Binge days/wk | Binges/wk (M,SD)  G1: 3.92 (1.47)  G2: 3.28 (1.31)  Binge days/wk (M,SD)  G1: 3.81 (1.39)  G2: 3.20 (1.26) | Binges/wk (M,SD)  G1: 1.65 (2.35)  G2: 0.76 (1.71)  Diff between groups (p = 0.151)  Diff between groups in change over time (p =0.958)  Binge days/wk (M, SD)  G1: 1.58 (2.212)  G2: 0.76 (1.71)  Diff between groups (p = 0.156)  Diff between groups in change over time (p =0.900)  Response Categories (% decrease in binges/wk from baseline to endpoint)  Intent to treat sample: G1 = 25; G2 = 24  None (<50%): G1: 5 (20); G2: 3 (13)  Moderate (50%-74% decrease): G1: 4 (16); G2: 2 (8)  Marked (75%-99% decrease): G1: 3 (12); G2: 1 (4)  Remission (100%): G1: 13 (52); G2: 18 (75) (P = NS)  Diff between groups (P = NS) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Guerdjikova, 200869 | Binge episodes/week  Binge days/week  Response categories for % decrease in frequency of binges from BL to endpoint  -none (<50%)  -moderate (50-74%)  -marked (75-99%)  -remission (100%) | Binge episodes/week, M (SD)  G1: 4.9 (2.6)  G2: 5.1 (2.3)  p=NS  Binge days/week, M (SD)  G1: 4.0 (1.7)  G2: 4.1 (1.5)  p=NS | Binge episodes/week, M (SD)  G1: 0.9 (1.4)  G2: 1.7 (1.5)  Time-trend analysis  Estimate between-group difference in 12-week change (95% CI): -0.27 (-0.50, 0.07)  chi-square: 2.7  p=0.100  Endpoint analysis  Estimate between-group difference in change from BL to final visit (95% CI): -0.31 (-0.52, 0.03)  t=2.17  p=0.036  Binge days/week, M (SD)  G1: 0.9 (1.4)  G2:1.6 (1.4)  Time-trend analysis  Estimate between-group difference in 12-week change (95% CI): -0.28 (-0.50, 0.05)  chi-square: 2.95  p=0.102  Endpoint analysis  Estimate between-group difference in change from BL to final visit (95% CI): -0.31 (-0.52, 0.01)  t=2.10  p=0.042  ITT analysis Response:  None  G1: 3 (15%)  G2: 5 (22%)  Moderate  G1: 3 (15%)  G2: 9 (39%) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Guerdjikova, 200869  (continued) |  |  | Marked  G1: 4 (20%)  G2: 3 (13%)  Remission  G1: 10 (50%)  G2: 6 (26%)  p=0.088 for difference between groups  Completer analysis Response:  None  G1: 2 (12%)  G2: 3 (16%)  Moderate  G1: 2 (12%)  G2: 8 (42%)  Marked  G1: 5 (29%)  G2: 2 (11%)Remission  G1: 8 (47%)  G2: 6 (32%)  p=0.176 for difference between groups |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Guerdjikova, 201270 | Binge day frequency - the number of days per week that a participant engaged in at least one binge episode  Binge episode frequency per week | Binge days/wk, M (SD)  G1: 4.0 (1.8)  G2: 3.5 (1.5)  p = NR  Binges/wk, M (SD)  G1: 4.5 (2.0)  G2: 4.0 (2.4)  p = NR | Binge days/wk, M (SD)  G1: 1.0 (1.7)  G2: 1.3 (1.2)  Longitudinal analysis  d = 0.67  p = 0.04  Endpoint analysis  d = 0.47  p = 0.15  Binges/wk, M (SD)  G1: 1.1 (2.0)  G2: 1.3 (1.2)  Longitudinal analysis  d = 0.78  p = 0.02  Endpoint analysis  d = 0.36  p = 0.27  Response:  None  G1: 3 (17%)  G2: 3 (30%)  Moderate  G1: 1 (6%)  G2: 4 (20%)  Marked  G1: 4 (22%)  G2: 4 (20%)  Remission  G1: 10 (56%)  G2: 6 (30%)  p=0.09 for difference between groups |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Hudson, 199871 | Binge frequency: Number of binges experienced since the last visit (visits were weekly)  Additional analyses examined categorical variable of % decrease in frequency of binges from BL to 9wk | Binges/wk, M (SD)  G1: 5.4 (2.9)  G2: 5.3 (2.5)  p=NR, NS | Binges/wk (intent-to-treat), in mean log ([binges/week]+1):  G1: depicted in graph  G2: depicted in graph  Treatment-by-time interaction:  -0.181 (SE 0.066)  p=0.006  G1 > G2  Response categories  ITT Analysis  Remission (100% decrease)  G1: 15 (38%)  G2: 11 (26%)  Marked response (75%-99% decrease)  G1: 3 (8%)  G2: 3 (7%)  Moderate response (50%-74% decrease)  G1: 7 (18%)  G2: 7 (16%)  No response (<50%)  G1: 15 (38%)  G2: 22 (51%)  Fisher's exact test, p = NR  Completer Analysis  Remission  G1: 13 (45%)  G2: 9 (24%)  Marked response  G1: 2 (7%)  G2: 3 (8%)  Moderate response  G1: 6 (21%)  G2: 6 (16%)  No response  G1: 8 (28%)  G2: 20 (53%)  Fisher's exact test, p = 0.04 |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Hudson, 199871  (continued) |  |  | Evaluable-subjects--those who completed 4wks):  Remission  G1: 15 (44%)  G2: 10 (24%)  Marked response  G1: 3 (9%)  G2: 3 (7%)  Moderate response  G1: 6 (18%)  G2: 7 (17%)  No response  G1: 10 (29%)  G2: 21 (51%)  Fisher's exact test, p = 0.04 |
| Leombruni, 200872 | Binges/week  Abstinence | Binges/wk  G1: 4.6 (3.2)  G2: 6.2 (7.3) | Binges/wk  T8  G1: 1.3 (1.9)  G2: 0.8 (1.1)  T12  G1: 1.3 (2.0)  G2: 0.6 (0.6)  T24  G1: 0.9 (1.1)  G2: 1.1 (3.3)  Time effect p = 0.000  Time x group p = 0.467 |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200773 | Binges/wk: binge frequency - mean # of binges per week in the interval between visits  Binge days/wk: weekly frequency of binge days - days when the pt. had 1 or more binges | Binges/wk:  G1: 4.2 (1.4)  G2: 4.9 (2.5)  Binge days/wk:  G1: 3.8 (1.1)  G2: 3.9 (1.5) | Binges/wk:  Longitudinal Analysis  Estimate (mean change btwn g1-g2): -0.41  95% CI: -0.61 to -0.09  X^2: 5.27  p: 0.81  Endpoint Analysis  Estimate (mean change btwn g1-g2):-0.16  95% CI: -0.29 to - 0.01  t: 2.20  p: 0.34  Binge days/wk:  Longitudinal Analysis  Estimate (mean change btwn g1 - g2): -0.45  95% CI: -0.63 to - 0.18  X^2: 8.75  p: 0.003  Endpoint Analysis  Estimate (mean change btwn g1 - g2): -0.16  95% CI: -0.30 to - 0.03  t: 2.37  p: 0.023 |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200674 | Binge frequency (mean number of binges per week)  Binge days/week  Binge response to treatment categories  -remission: cessation of binges  -marked: 75%-99% decrease  -moderate: 50-74% decrease  -none: <50% decrease  Time to recovery (recovery = first 4 conse | Binges/wk, mean (SD):  G1: 4.7 (SD 1.4)  G2: 4.4 (SD 2.0)  Binge days/wk, mean (SD):  G1: 3.9 (SD 1.1)  G2: 3.9 (SD 1.3) | Binges/wk  Longitudinal analysis  G1: NR  G2: NR  Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -0.315 (95% CI -0.504 to -0.055); log transformation (log [binges/week]+1) was used for analysis, but these values are expressed in the original scale  p=0.021  Endpoint analysis  G1: NR  G2: NR  Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): 0.002 (95% CI -0.143 to 0.171); log transformation (log [binges/week]+1) was used for analysis, but these values are expressed in the original scale  p=0.979  Binge days/wk  Longitudinal analysis  G1: NR  G2: NR  Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -0.271 (95% CI -0.476 to 0.016); log transformation (log [binges/week]+1) was used for analysis, but these values are expressed in the original scale |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200674  (continued) |  |  | p=0.082  Endpoint analysis  G1: NR  G2: NR  Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): -0.040 (95% CI -0.176 to 0.119); log transformation (log [binges/week]+1) was used for analysis, but these values are expressed in the original scale  p=0.596  Categorical response: ITT analysis  None  G1: 5 (18%)  G2: 4 (14%)  Moderate  G1: 4 (14%)  G2: 7 (24%)  Marked  G1: 4 (14%)  G2: 5 (17%)  Remission  G1: 15 (54%)  G2: 13 (45%)  p=0.82 (NS difference between groups) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200375 | Binge frequency: Number of binges experienced since the last visit (visits were weekly), per clinical interview and review of take-home diaries  Weekly frequency of binge days (days during which there were 1 or more binges)  Additional analyses examined c | Binges/wk, mean (SD)  G1: 5.2 (3.6)  G2: 5.7 (2.6)  p=NR, NS  Binge days/wk  G1: 4.0 (1.7)  G2: 4.0 (1.5)  p=NR, NS | Binges/wk, mean (SD)  G1: 1.7 (3.1)  G2: 3.4 (3.0)  Time Trend Analysis: Diff b/t groups in rate of change, standardized at 5.5 binges/wk:  -1.7  p = 0.003  Endpoint Analysis: Diff b/t groups in change from BL to 6wk, standardized at 5.5 binges/wk:  -1.1  p = 0.091  Binge days/wk, mean (SD)  G1: 1.2 (2.0)  G2: 2.8 (2.2)  Time Trend Analysis: Diff b/t groups in rate of change, standardized at 4.0 binge days/wk:  -1.6  p < 0.001  Endpoint Analysis: Differences between groups in change from BL to 6wk, standardized at 4.0 binge days/wk:  -1.2  p = 0.016  Response categories  ITT Analysis:  None (<50%)  G1: 5 (26)  G2: 11 (58)  Moderate (50-74%)  G1: 4 (21)  G2: 3 (16)  Marked (75-99%)  G1: 1 (5)  G2: 1 (5) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200375  (continued) |  |  | Remission (100%)  G1: 9 (47)  G2: 4 (21)  p=0.068 for difference between groups, by exact trend test |
| McElroy, 200376 | Binges/wk  Binge days/wk  Categorical response:  None (< 50% reduction)  Moderate (50% to 74% reduction)  Marked (75% to 99% reduction)  Remission (100% reduction - zero binges) | Binges/wk, mean (SD):  G1: 5.3 (2.8)  G2: 6.3 (2.8)  Binge days/wk, mean (SD):  G1: 4.3 (1.8)  G2: 4.8 (1.8) | Binges/wk (% decrease)  G1: 94%  G2: 46%  Diff between groups, p = NS  Diff between groups in change over time, p = 0.02  Diff between groups in rate of change, p = 0.0004  Binge Days/wk (% decrease)  G1: 93%  G2: 46%  Diff between groups, p = NS  Diff between groups in change over time, p = 0.02  Diff between groups in rate of change, p = 0.0001  Categorical Response, %:  None:  G1: 18%  G2: 37%  Moderate:  G1: 7%  G2: 23%  Marked:  G1: 11%  G2: 10%  Remission:  G1: 64%  G2: 30% |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200077 | Binges per week | Binges/wk, mean (SD):  G1: 7.6 (4.8)  G2: 7.2 (5.8)  p = 0.83  G1: LOG: 2.04 (0.48)  G2: LOG: 1.97 (0.52)  p = 0.69 | Binges/wk:  Difference in change between G1 and G2, mean, expressed as log([binges/wk]+1): -0.441  SE:0.163  p = 0.008  G1 better than G2  Among completers:  Binges/wk  G1: 1.13 (1.56)  G2: 3.85 (3.81)  Categorical response. N:  None (< 50% reduction)  G1: 0  G2: 3  Moderate (50% to 74% reduction)  G1: 3  G2: 4  Marked (75% to 99% reduction)  G1: 2  G2: 3  Remission (100 % reduction)  G1: 7  G2: 2 |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 201178 | Binge episode frequency per week  Binge day frequency - the number of days per week that a participant engaged in at least one binge episode  Categorical response:  None (< 50% reduction)  Moderate (50% to 74% reduction)  Marked (75% to 99% reduction)  Remiss | Binges episodes/wk, mean (SD)  G1: 4.5 (2.1)  G2: 4.5 (2.2)  p = NR, NS  Bingedays/wk, mean (SD)  G1: 4.2 (1.7)  G2: 3.8 (1.2)  p = NR, NS | Binges episodes/wk, mean (SD)  G1: 1.9 (2.4)  G2: 2.8 (2.5)  p = 0.61  Binge days/wk, mean (SD)  G1: 1.8 (2.2)  G2: 2.6 (2.1)  p = 0.23  Categorical Response:  None:  G1: 32%  G2: 50%  Moderate:  G1: 21%  G2: 20%  Marked:  G1: 16%  G2: 10%  Remission:  G1: 32%  G2: 20%  p = NR, stated as NS |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 200779 | Binge episode frequency per week  Binge day frequency - the number of days per week that a participant engaged in at least one binge episode  Categorical response, binge days:  None (< 50% reduction)  Moderate (50% to 74% reduction)  Marked (75% to 99% reduc | Binges episodes/wk, mean (SD)  G1: 6.6 (4.6)  G2: 6.3 (3.6)  p = NR  Bingedays/wk, mean (SD)  G1: 4.6 (1.3)  G2: 4.6 (1.3)  p = NR | Binge episodes/wk, mean (SD) change from baseline  G1: -3.5 (1.9)  G2: -2.5 (2.1)  Endpoint Analysis: p < 0.001  Longitudinal Analysis, rate of change: p < 0.001  Binge days/wk, mean (SD) change from baseline  G1: -5.0 (4.3)  G2: -3.4 (3.8)  Endpoint Analysis: p < 0.001  Longitudinal Analysis, rate of change: p < 0.001  Categorical response, binge days:  None  G1: 20%  G2: 42%  Moderate  G1: 10%  G2: 18%  Marked  G1: 12%  G2: 11%  Remission  G1: 58%  G2: 29%  p < 0.001 for group difference across categories |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 201380 | Binge days/wk  Binge days responder categories  -≥1 less day  -≥2 less day  -≥3 less day  Weekly binge frequency  Weekly binge frequency responder categories  -≥2 binges  -≥3 binges  -≥4 binges  Remission: no binges in the last 2 study weeks or in interval be | Binge days/wk, mean (SD)  G1: 3.4 (1.0)  G2: 3.7 (1.5)  p=0.35  Binges/wk, mean (SD)  G1: 4.4 (2.3)  G2: 4.3 (2.3)  p=0.87 | Endpoint means NR  Weekly binge days, mean change (SD) from baseline to endpoint:  G1: -2.4 (1.6)  G2: -2.7 (.5)  p=0.50  Binge days responder-≥1 day, N (%) from baseline to endpoint, N (%):  G1: 20 (77%)  G2: 32 (89%)  p=0.30  Binge days responder-≥2 day, N (%) from baseline to endpoint:  G1: 18 (69%)  G2: 24 (67%)  p=0.83  Binge days responder-≥3 day, N (%) from baseline to endpoint:  G1: 11 (42%)  G2: 18 (50%)  p=0.55  Weekly binge frequency, mean change (SD) from baseline to endpoint:  G1: -3.3 (2.4)  G2: -3.2 (1.8)  p=0.99  Binge frequency responder-≥2 binges, N (%) from baseline to endpoint:  G1: 19 (73%)  G2: 26 (SD 72%)  p=0.94  Binge frequency responder-≥3 binges, N (%) from baseline to endpoint:  G1: 16 (SD 62%)  G2: 20 (SD 56%)  p=0.64 |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 201380  (continued) |  |  | Binge frequency responder-≥4 binges, N (%) from baseline to endpoint:  G1: 10 (38%)  G2: 13 (SD 36%)  p=0.85  Remission, N (%)  G1: 9 (35%)  G2: 19 (53%)  p=0.16 |
| McElroy, 201581 | Binge days per week | Binge days/week, nontransformed mean (SD)  G1: 4.5 (SD 1.44)  G2: 4.5 (SD 1.28)  G3: 4.6 (SD 1.25)  G4: 4.3 (SD 1.38)  Binge episodes, non-transformed, mean (SD)  G1: 5.8 (SD 3.03)  G2: 5.6 (SD 2.75)  G3: 5.6 (SD 2.43)  G4: 5.2 (SD 2.13) | Primary efficacy variables  11wk Binge days/week, nontransformed mean (SD)  G1: 1.0 (SD 1.69)  G2: 0.4 (SD 0.86)  G3: 0.5 (SD 1.25)  G4: 1.1 (SD 1.45)  11wk change from BL, Binge days/week, log-transformed, LS, mean (SE)  G1: -1.24 (SE 0.067)  G2: -1.49 (SE 0.066)  G3: -1.57 (SE 0.067)  G4: -1.23 (SE 0.069)  11wk difference from placebo, Binge days/week, nontransformed mean (SD)  G1: -0.01 (SE 0.096)  G2: -0.26 (SE 0.096)  G3: -0.35 (SE 0.096)  G4: N/A  Binge days/week Significant difference compared with placebo  G1 p=0.88  G2 p=0.008  G3 p<0.001  G4 N/A |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 201581  (continued) |  |  | Secondary efficacy variables  11wk binge episodes, non-transformed, mean (SD)  G1: 1.2 (SD 2.13)  G2: 0.5 (SD 1.01)  G3: 0.5 (SD 1.34)  G4: 1.1 (SD 1.55)  11wk change from BL, Binge episodes, log-transformed, LS, mean (SE)  G1: -1.37 (SE 0.070)  G2: -1.62 (SE 0.069)  G3: -1.71 (SE 0.070)  G4: -1.36 (SE 0.072)  11wk difference from placebo, Binge episodes, nontransformed mean (SD)  G1: -0.01 (SE 0.100)  G2: -0.27 (SE 0.100)  G3: -0.35 (SE 0.100)  G4: N/A  Binge episodes Significant difference compared with placebo  G1 p=0.89  G2 p=0.009  G3 p<0.001  G4 N/A  1wk Cessation (100% reduction) Binge response category (%)  G1: 42.4%  G2: 51.6%  G3: 55.6%  G4: 37.1%  1wk Marked response (75-<100% reduction) Binge response category (%)  G1: 30.3%  G2: 37.5%  G3: 36.5%  G4: 24.2% |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| McElroy, 201581  (continued) |  |  | 1wk Moderate response (50-<75 reduction) Binge response category (%)  G1: 12.1%  G2: 6.3%  G3: 1.6%  G4: 21.0%  1wk Negative/minimal response (<25% reduction) Binge response category (%)  G1: 15.2%  G2: 4.7%  G3: 6.3%  G4: 17.7%  1wk Binge category response: Significant difference compared with placebo  G1 p=0.33  G2 p=0.006  G3 p=0.002  G4 N/A  4wk Cessation (100% reduction) Binge response category (%)  G1: 34.9%  G2: 42.2%  G3: 50.0%  G4: 21.3%  4wk Binge cessation: Significant difference compared with placebo  G1 p=0.09  G2 p=0.01  G3 p<0.001  G4 N/A |
| Pearlstein, 200382 | Number of binge days, past 28 days | Days Binged (M,SD)  G1: 14.67 (55.68)  G2: 20.00 (6.21)  (P = NS) | Days Binged (M,SD)  G1: 3.11 (4.20)  G2: 7.31 (9.31)  Diff between groups (P = NR)  Change over time for both groups: (P < 0.001)  Diff between groups in change over time (P=NS) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| Shire, 201483,84 | Number of binge days per week  4-week abstinence | Number of binge days per week  G1: 4.66 (1.27)  G2: 4.82 (1.42) | Change in number of binge days per week measured as LS mean (SEM)  G1: -3.92 (0.135) SD: 0.14  G2: -2.26 (0.137) SD: 0.14  LS Mean diff (95% CI): -1.66 (-2.04 to -1.28)  (p< 0.001)  4-week abstinence  G1: 36.2% (29.1-43.3)  G2: 13.1% (8.1-18.0)  Diff: 25.9% (p < 0.001)  Change in number of binge episodes per week  G1: -5.54 (0.193)  G2: -3.31 (0.194)  Diff: -2.23 (-2.77 to -1.69) (p < 0.001) |
| Shire, 201484,85 | Number of binge days, past 28 days | Days Binged (M,SD)  G1: 14.67 (55.68)  G2: 20.00 (6.21)  (P = NS) | Days Binged (M,SD)  G1: 3.11 (4.20)  G2: 7.31 (9.31)  Diff between groups (P = NR)  Change over time for both groups: (P < 0.001)  Diff between groups in change over time (P=NS) |

Evidence Table 59. Binge eating disorder drug treatment – part 5 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Binges (days; frequency; remission; abstinence etc.) | Binges Baseline | Binges Outcomes |
| White, 201386 | Objective binge eating (OBE) episodes, EDE monthly  Objective binge eating (OBE) episodes, self-report weekly (via daily monitoring)  Subjective binge eating (SBE) episodes, EDE monthly  Subjective binge eating (SBE) episodes, self-report weekly (via dail | OBE episodes, EDE monthly  G1: 17.8 (SD 11.9)  G2: 13.6 (SD 6.5)  OBE episodes, SR weekly  G1: 3.3 (SD 3.3)  G2: 3.0 (SD 2.6)  SBE episodes, EDE monthly  G1: 13.5 (SD 11.2)  G2: 10.3 (SD 14.2)  SBE episodes, SR weekly  G1: 3.6 (SD 2.7)  G2: 2.7 (SD 3.4) | 8wk OBE episodes, EDE monthly  G1: 5.0 (SD 9.4)  G2: 6.3 (SD 8.0)  Mixed effects model medication effect  F=0.08, p=0.78  8wk OBE episodes, SR weekly  G1: 0.8 (SD 1.2)  G2: 1.0 (SD 1.5)  Mixed effects model medication effect  F=2.01, p=0.16  8wk SBE episodes, EDE monthly  G1: 9.3 (SD 21.4)  G2: 7.5 (SD 8.4)  Mixed effects model medication effect  F=0.96, p=0.33  8wk SBE episodes, SR weekly  G1: 2.2 (SD 4.2)  G2: 2.3 (SD 2.4)  Mixed effects model medication effect  F=0.47, p=0.50  8wk Categorical remission from binge episodes (no binge episodes during the past 4 weeks)  G1: 42%  G2: 27%  Chi-square=1.58, phi coefficient=0.16, p=0.21 |